Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Acquires Rights to Investigational Heart Attack Drug from Bayer

NEW YORK, Nov. 17 (GenomeWeb News) - DeCode Genetics said this week that it has acquired from Bayer the exclusive worldwide rights to a small molecule compound active against a target made by a gene that predisposes to myocardial infarction.

 

Under the deal, Bayer will be paid clinical development milestones, as well as royalties on future sales of the drug.

 

DeCode said that it plans to begin testing the compound, called DG031, for efficacy in a phase II trial beginning in early 2004. Additional information about the investigational drug, said DeCode, will be made available in a scientific paper that will be submitted for publication at the beginning of the study.

 

"This is a transforming event for DeCode," DeCode CEO Kari Stefansson said in a statement. "By licensing an existing compound already found to be well-tolerated, designed against one of our key targets in myocardial infarction, we will be able to leapfrog several stages in the drug development process."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.